Contents
On this page
- The problem GPP was developed to address
- 2003: the first edition of GPP
- 2009: GPP2 and the formalisation of principles into written agreements
- 2015: GPP3 and the broadening of authorship of the guideline
- 2022: GPP 2022 and the extension beyond journal publications
- Patterns across four revisions
- The increasing visibility of the professional medical writer
- Effects of the revisions on manuscript content
- Questions not resolved by four revisions
- Key points
- Application to your study
- Frequently asked questions
Academy · Research Publication · Evolution of GPP
The Evolution of Good Publication Practice: Four Editions and the Events That Prompted Them
GPP has been revised three times since 2003, and each revision was substantive. Each followed either a documented controversy concerning industry influence on the literature or a change in journal and regulatory requirements. Reading the editions in sequence clarifies the problems the guideline is intended to address.
Good Publication Practice (GPP) is often encountered as a compliance obligation: a document cited by a sponsor’s publications team when requesting a signature. Read in isolation, its requirements may appear arbitrary. Read in sequence (2003, 2009, 2015, 2022), it constitutes a record of specific failures and the clauses written to prevent their recurrence. The written sponsor–author agreement exists because of what occurred in its absence, and the rule on disclosing writing support exists because of ghostwriting documented in court filings. Understanding which clause addresses which failure facilitates application of the current edition.
Learning objectives
- What each of the four GPP editions added, and what prompted it
- The breadth of consultation at each revision, from 70 companies in 2000 to over 120 comment sets in 2022
- Why GPP2 moved from stating principles to specifying a written agreement with named responsibilities
- How the position of the professional medical writer changed from undisclosed to named and funded
- Which parts of GPP respond to external rules, such as trial registration and data sharing, rather than to internal consensus
- What four revisions have not yet established about whether GPP adherence changes outcomes
Common misconceptions
- “GPP is an industry document written by and for industry.” The first draft was circulated to 70 companies, but each later revision widened the authorship deliberately: GPP2 invited 193 people and received 116 sets of comments, and GPP3 drew its 18-member steering committee from 241 applications across 7 countries.
- “The editions are largely similar, so an older edition is sufficient.” This is incorrect. GPP2 introduced the written sponsor–author agreement with itemised responsibilities; GPP 2022 extended scope well beyond the journal article. A team working to GPP2 is two editions behind.
- “GPP exists to protect companies from criticism.” Its clauses correspond to specific documented failures: guest authorship and ghostwriting in the rofecoxib publications, the ADVANTAGE seeding trial, and selective non-publication of unfavourable results. The guideline can be read as a record of those failures.
- “Following GPP has been shown to improve the literature.” This has not been tested. The published evaluations measure declared professional writing support against reporting checklists, which is a different question, as discussed below.
The problem GPP was developed to address
By the late 1990s, three failures in company-sponsored publication had been documented sufficiently for medical journals to discuss them openly. The first was selective publication: trials with unfavourable results were not published. Easterbrook and colleagues had demonstrated the pattern in Lancet, Stern and Simes had traced the mechanism of delay in BMJ, and by 2003 Antes and Chalmers were arguing in Lancet that under-reporting of trials was not a methodological inconvenience but an ethical breach, because patients had consented on the understanding that the results would be used 28,31,32.
The second failure concerned control of the manuscript. Davidoff and colleagues set out the problem in Annals of Internal Medicine under the title “Sponsorship, authorship, and accountability”: where a sponsor held the data, drafted the paper and retained the right to decide whether it was published, the named academic authors were not in a position to be accountable for it, regardless of the author line 29.
The third failure concerned the author line itself. Rennie, Flanagin and Yank had argued in JAMA for describing contributions rather than asserting authorship, precisely because the assertion had become unfalsifiable 30. None of these observations was new in 2003; what was lacking was a document that gave a company’s publications staff practical, operational guidance.
2003: the first edition of GPP
The initiative began with a retreat in 1998 organised by the Council of Biology Editors together with industry participants 26. A draft was developed from this meeting and circulated to 70 companies for comment in 2000. The result was published by Wager, Field and Grossman in Current Medical Research and Opinion in 2003, in volume 19, issue 3: an editorial at pages 147 to 148 explaining why a further set of guidelines was needed, followed by the guidelines themselves at pages 149 to 154 26,27.
The editorial is the more informative of the two documents, because it had to answer an obvious objection: the ICMJE Recommendations already existed. The argument was that the ICMJE Recommendations address what authors and editors must do and say little about what a sponsor must do, and that in company-sponsored research the sponsor makes most of the decisions that matter 1,27. GPP 2003 therefore set out expectations for the sponsor: to publish results whether favourable or not, not to use publications as a marketing instrument, to acknowledge writing assistance, and to leave authorship decisions to the ICMJE criteria.
It comprised six pages, was based on principles, and provided no mechanism for implementation. This was its limitation and the reason it required replacement.
2009: GPP2 and the formalisation of principles into written agreements
Between 2003 and 2009, the evidence deteriorated considerably, and it did so publicly. Ross and colleagues, in JAMA, analysed internal documents released in the rofecoxib litigation and showed that guest authorship and ghostwriting operated as routine practice rather than as isolated lapses 16. Hill and colleagues, in Annals of Internal Medicine, reviewed the internal documents of the ADVANTAGE trial and described a study designed primarily to seed prescribing 19. Angell, in JAMA, described industry-sponsored clinical research as a broken system 17. Gotzsche and colleagues, in PLoS Medicine, asked what should be done about ghostwriting in the medical literature 15. Rothman and colleagues, in JAMA, proposed controls on professional associations’ relationships with industry, and Woloshin and colleagues showed in Annals of Internal Medicine that even academic press releases overstated findings 13,14.
GPP2, published by Graf and colleagues in BMJ in 2009, responded with specificity rather than further principles. Its consultation invited 193 people and received 116 sets of comments 12. Its central addition was the written agreement between sponsor and authors, settled before drafting begins, with responsibilities itemised: 3 belonging to the sponsor, 9 to the authors and 8 shared between them 12. It included 4 supporting tables, including a checklist for articles and presentations and a checklist of basic requirements for written agreements, and cited 29 references 12.
The change from the 2003 edition is a change from “sponsors should not control publication” to “here is the document in which control is allocated, here is who signs it, and here is when”. Almost every element that a modern publications team recognises as GPP compliance dates from this edition.
2015: GPP3 and the broadening of authorship of the guideline
GPP3, published by Battisti and colleagues in Annals of Internal Medicine in 2015, was the first revision to treat the breadth of its own authorship as a substantive issue 8. The International Society for Medical Publication Professionals (ISMPP) invited more than 3,000 publication professionals worldwide either to apply for the steering committee or to serve as reviewers 8. The GPP2 authors reviewed 241 applications and formed an 18-member steering committee drawn from 7 countries 8.
This process is significant for a reason beyond legitimacy. A guideline for company-sponsored publication written by a small group from one or two markets will encode the assumptions of those markets regarding what a sponsor may request, what constitutes normal acknowledgement practice, and which regulators exercise oversight. Drawing the committee from seven countries and opening the reviewer pool corrected this, and it is the clearest institutional difference between GPP2 and GPP3.
Substantively, GPP3 is the edition in which the guideline became usable as a day-to-day reference rather than a statement of position. The current requirements are set out item by item in the GPP reporting standards reference; their application to a live publication is described in the worked application page.
Scale of consultation at each revision, as reported by the authors of each edition. Sources: Wager E, Field EA, Grossman L, Current Medical Research and Opinion (2003); Graf C et al., BMJ (2009); Battisti WP et al., Annals of Internal Medicine (2015); International Society for Medical Publication Professionals announcement of GPP 2022.
2022: GPP 2022 and the extension beyond journal publications
GPP 2022, from DeTora and colleagues in Annals of Internal Medicine, was developed with feedback from 38 invited experts before submission and an open reviewer call that returned more than 120 sets of comments representing the input of hundreds of professionals 4,5. ISMPP described the process in its own announcement of the publication.
The defining change is scope. The earlier editions assumed that the output being governed was a journal article or a congress presentation. By 2022, this assumption no longer held: the same trial results reach their audiences through plain-language summaries, enhanced digital content, registry postings, slide sets and material intended for patients rather than clinicians, and none of these clearly fell within the remit of the older editions. GPP 2022 extended the principles to the full set of outputs 5.
Recent and ongoing changes are discussed separately in recent trends in GPP. The general ethical framework within which GPP operates is described in the publication ethics hub.
Patterns across four revisions
Two forces drive the revisions, and they alternate. The first is disclosure: a set of internal documents becomes public, a practice assumed to be rare proves to be systematic, and the next edition addresses it. The 2009 edition is the clearest example.
The second is external rule change, in which GPP adopts requirements that journals or regulators have already imposed. Prospective trial registration is the standard example: Steinbrook, writing in the New England Journal of Medicine, described the move to public registration of clinical trials, and once registration became a condition of publication rather than an optional practice, a publication guideline had to assume it 24. The same occurred later with data sharing statements, which the ICMJE made a requirement for manuscripts reporting clinical trial results 1.
The practical consequence is that GPP consistently lags slightly behind the journals. When deciding how to address a matter that the current edition does not cover, the more useful question is usually not “what does GPP say?” but “what do the target journals already require?”, because that is likely to be what the next edition will state.
Four editions, and what moved each one
| Edition | Where published | Consultation | The addition that defines it |
|---|---|---|---|
| GPP (2003) | Wager, Field & Grossman, Current Medical Research and Opinion 19(3):149–154, with editorial at 147–148 | 1998 retreat; draft circulated to 70 companies in 2000 | The first statement of sponsor obligations: publish regardless of result, acknowledge writing assistance, leave authorship to the ICMJE criteria |
| GPP2 (2009) | Graf et al., BMJ | 193 invited; 116 sets of comments | The written sponsor–author agreement, with 3 sponsor, 9 author and 8 shared responsibilities; 4 supporting tables and 29 references |
| GPP3 (2015) | Battisti et al., Annals of Internal Medicine | Over 3,000 professionals invited; 241 applications; 18-member steering committee from 7 countries | A deliberately international and openly recruited authorship, and a document usable as a working reference |
| GPP 2022 | DeTora et al., Annals of Internal Medicine | 38 invited experts; over 120 sets of comments from the open call | Scope extended past the journal article to the full set of outputs, including plain-language and enhanced content |
Publication details and consultation figures as reported in each edition’s own account of its development, and in the ISMPP announcement of GPP 2022. Consultation processes differed between editions and the figures are not directly comparable.
The increasing visibility of the professional medical writer
Alongside the GPP editions runs a second sequence of documents that explains the current form of acknowledgement wording. In 2003, Hamilton and Royer published the American Medical Writers Association (AMWA) position statement on the contributions of medical writers to scientific publications 25. In 2005, Jacobs and Wager published the European Medical Writers Association (EMWA) guidelines on the role of medical writers in developing peer-reviewed publications in Current Medical Research and Opinion 22. In 2007, Norris and colleagues published the ISMPP position statement in the same journal 20.
All three express a version of the same position: professional writing support is legitimate, it does not constitute authorship unless the ICMJE criteria are met, and the appropriate response to ghostwriting is disclosure rather than prohibition. This position is now standard, but it was contested when first stated, and evidence that it has not been fully absorbed continues to appear. Wislar and colleagues, in BMJ, found inappropriate authorship persisting in leading general medical journals years after these statements were published 9. The intersection between writing support and the authorship rules themselves is discussed in using the ICMJE Recommendations.
Effects of the revisions on manuscript content
Expressed as principles, these developments can appear more substantial than they are. In the manuscript, four editions of revision amount to a small number of additional clauses in two short statements. The pair below presents the acknowledgement and contributorship text for the same hypothetical trial, written as it would commonly have appeared under the 2003 edition and as it would be written under GPP 2022.
Acknowledgement and contributorship for the same trial, under the 2003 edition and under GPP 2022
Typical under GPP 2003
Acknowledgements: The authors acknowledge the editorial assistance of ABC Medical Communications in the preparation of this manuscript, supported by XYZ Pharma. All authors contributed to and approved the manuscript.
“Editorial assistance” names a company, not a person. No individual is accountable for what was written, which is the precise condition described in the ghostwriting literature.
No scope. “Preparation of this manuscript” is consistent both with light copy-editing and with drafting the entire paper.
“All authors contributed” is an assertion, not a description. It cannot be checked against the ICMJE criteria, which is what made the claim unfalsifiable in the first place.
Silence on the sponsor’s role. Data custody, the person who performed the analysis, and who could have prevented publication are all unstated.
Expected under GPP 2022
Contributorship: J.K. and L.M. designed the study. L.M. and the sponsor’s clinical operations team acquired the data. N.O., a statistician employed by the sponsor, conducted the pre-specified analyses; J.K. and P.Q. interpreted the results. J.K. drafted the manuscript from an outline agreed by all authors, and all authors critically revised it, approved the final version and agree to be accountable for its integrity. Acknowledgements: Medical writing support was provided by Jane Smith, PhD, of ABC Medical Communications, funded by XYZ Pharma, and comprised drafting from the author-agreed outline, incorporating author revisions, and reference checking. Dr Smith does not meet ICMJE authorship criteria and is named with her consent. Role of the sponsor: XYZ Pharma designed the trial with the academic steering committee, held the database and conducted the primary analysis; all authors had access to the full dataset and the decision to submit rested with the authors, as set out in the written agreement signed before drafting began.
The writer is named, with employer, funder, itemised scope, the reason she is not an author, and her consent to be named.
Each author’s contribution is described, so the four ICMJE criteria can be checked rather than taken on trust.
The sponsor’s statistician is identified as a sponsor employee, which is information a reader needs and is not a problem in itself.
The sponsor’s role is itemised, and author control of submission is tied to a written agreement that predates drafting, which is the GPP2 mechanism and remains the core of the current edition.
Nothing in the second version changes a decision; it records decisions that had already been made. Twenty years of revision largely amount to this: moving facts from the sponsor’s internal files into the published record, where readers can evaluate them.
Questions not resolved by four revisions
There is no published evaluation of whether adherence to GPP produces any measurable change in the literature, and this should be stated plainly rather than implied otherwise. The studies commonly cited, Gattrell and colleagues in BMJ Open, Mills and colleagues in F1000Research — examine whether declared professional medical writing support is associated with more complete reporting against the Consolidated Standards of Reporting Trials (CONSORT). That is a useful question, but a different one 6,7. Declared writing support is a proxy for a professionalised publication process, not a measure of GPP compliance, and the two studies do not in any case agree with each other.
Nor has the proportion of company-sponsored publications that actually comply been established. The consultation figures indicate how many professionals were asked to comment on the guideline; they provide no information about uptake. Titus, Wells and Rhoades argued in Nature that research integrity requires institutional repair rather than additional codes, and on the available evidence that argument has not been answered for publication guidelines specifically 18. GPP is best regarded as a defensible standard of practice whose effectiveness has not been demonstrated, which nonetheless remains preferable to the absence of any standard.
Key points
Key points
GPP has four editions, and the differences between them are substantive. The 2003 edition stated sponsor obligations. GPP2 in 2009 supplied the mechanism, a written sponsor–author agreement with itemised responsibilities, in direct response to the rofecoxib and ADVANTAGE disclosures. GPP3 in 2015 broadened authorship of the guideline, drawing an 18-member committee from 241 applications across 7 countries. GPP 2022 extended scope beyond the journal article to the full range of outputs. Each revision followed either a public disclosure of poor practice or a rule that journals had already imposed; the guideline therefore tends to lag journal requirements, and where the current edition is silent, target journals’ current requirements should be consulted.
Application to your study
Application to your study
- Authors should verify which edition the sponsor’s standard operating procedures were written against. Documents still citing GPP2 or GPP3 are one or two editions out of date, and the gap is mostly about scope and non-journal outputs.
- The written sponsor–author agreement should be located before drafting begins. If none exists, the GPP2 mechanism is absent, and it is the element most difficult to introduce retrospectively once a draft is in circulation.
- The agreement should state explicitly that the decision to submit rests with the authors. This clause addresses the accountability problem described by Davidoff and colleagues.
- The phrase “all authors contributed and approved” should be replaced with a contributorship statement that describes each person’s actual contribution. An assertion cannot be verified; a description can.
- Writing support should be identified by person, employer, funder and scope, and the writer’s consent to be named should be recorded. “Editorial assistance from” a company is the 2003 formulation and is now likely to be read as concealment.
- The sponsor’s role should be stated as a list, covering design, data custody, analysis and the decision to submit, rather than as the word “supported”.
- Where the current edition is silent, the target journals’ instructions should be consulted. Historically, current journal requirements have tended to anticipate the next edition.
- Authors should not claim that GPP adherence improves the literature. No published evaluation tests that, and the writing-support studies answer a different question.
Frequently asked questions
Four. The original Good Publication Practice for pharmaceutical companies was published by Wager, Field and Grossman in Current Medical Research and Opinion in 2003, in volume 19 issue 3 at pages 149 to 154, with a companion editorial at pages 147 to 148. GPP2 followed from Graf and colleagues in BMJ in 2009, GPP3 from Battisti and colleagues in Annals of Internal Medicine in 2015, and GPP 2022 from DeTora and colleagues in the same journal. GPP 2022 is the current edition and the one to which work should conform. Internal procedures still citing GPP2 or GPP3 should be re-examined, because the scope changed substantially at the most recent revision.
Because the ICMJE Recommendations address what authors and editors must do and say comparatively little about what a sponsor must do, whereas in company-sponsored research the sponsor makes many of the decisions that determine whether a publication is honest. Wager, Field and Grossman made precisely this argument in their 2003 editorial explaining why a further set of guidelines was needed. Davidoff and colleagues had set out the underlying problem in Annals of Internal Medicine: where a sponsor holds the data, drafts the paper and can decide whether it appears, the named authors are not in a position to be accountable for it. GPP addresses the sponsor side; it supplements ICMJE rather than replacing it.
GPP2 supplied a mechanism where the 2003 edition had stated principles. Its central addition was a written agreement between sponsor and authors, settled before drafting begins, with itemised responsibilities: 3 belonging to the sponsor, 9 to the authors and 8 shared. It included 4 supporting tables, including a checklist for articles and presentations and a checklist of basic requirements for written agreements, and cited 29 references. Its consultation invited 193 people and received 116 sets of comments. Almost every element that a publications team now recognises as GPP compliance (the agreement, the checklists and the itemised sponsor role) dates from this edition.
A series of public disclosures between 2003 and 2009 concerning how industry publications were actually produced. Ross and colleagues, in JAMA, analysed internal documents released in the rofecoxib litigation and found that guest authorship and ghostwriting operated as routine practice. Hill and colleagues, in Annals of Internal Medicine, reviewed the ADVANTAGE trial’s internal documents and described a trial designed primarily to seed prescribing. Angell described industry-sponsored clinical research as a broken system in JAMA, and Gotzsche and colleagues asked in PLoS Medicine what should be done about ghostwriting. GPP2 can be read as a response to that body of evidence rather than as a routine update.
ISMPP invited more than 3,000 publication professionals worldwide either to apply for the steering committee or to serve as reviewers. The GPP2 authors reviewed 241 applications and formed an 18-member steering committee drawn from 7 countries. This is significant for a practical reason: a guideline written by a small group from one or two markets encodes the assumptions of those markets about what a sponsor may request and what constitutes normal acknowledgement practice. Opening the recruitment and drawing the committee from seven countries provided the correction, and it is the clearest institutional difference between GPP2 and GPP3.
No published evaluation tests that question, and this should be stated rather than implied otherwise. The studies usually offered in its place, Gattrell and colleagues in BMJ Open and Mills and colleagues in F1000Research, examine whether declared professional medical writing support is associated with more complete reporting against CONSORT. That is a proxy for a professionalised process, not a measure of GPP compliance, and the two studies do not agree with each other. Nor has the proportion of company-sponsored publications that comply with the current edition been established. GPP is a defensible standard whose effectiveness has not been demonstrated.
Because a substantial part of each revision consists of adopting external requirements rather than setting them. Prospective trial registration is the clearest example: Steinbrook described the move to public registration in the New England Journal of Medicine, and once registration had become a condition of publication, a publication guideline had to assume it. The same occurred with data sharing statements, which the ICMJE made a requirement for manuscripts reporting clinical trial results. The practical implication is that, where the current edition is silent on a matter, the target journals’ instructions are the better guide and probably indicate what the next edition will state.
References
- International Committee of Medical Journal Editors. Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals. ICMJE. 2026. read 9 October 2026. icmje.org
- International Committee of Medical Journal Editors. The New ICMJE Recommendations (August 2013). ICMJE. 2013. read 9 October 2026. icmje.org
- Committee on Publication Ethics. Core Practices. COPE. read 9 October 2026. equator-network.org
- International Society for Medical Publication Professionals. GPP 2022: Good Publication Practice guidelines for company-sponsored biomedical research published in Annals of Internal Medicine (press release). ISMPP. 2022. read 9 October 2026. ismpp.org
- DeTora LM, Toroser D, Sykes A, Vanderlinden C, Plunkett FJ, Lane T, Hanekamp E, Dormer L, DiBiasi F, Bridges D, Baltzer L, Citrome L. Good Publication Practice (GPP) Guidelines for Company-Sponsored Biomedical Research: 2022 Update. Annals of Internal Medicine. 2022;175(9):1298-1304. doi:10.7326/M22-1460 read 9 October 2026. doi.org/10.7326/M22-1460
- Mills I, Sheard C, Hays M, Douglas K, Winchester CC, Gattrell WT. Professional medical writing support and the reporting quality of randomized controlled trial abstracts among high-impact general medical journals. F1000Research. 2017;6:1489. doi:10.12688/f1000research.12268.2 read 9 October 2026. doi.org/10.12688/f1000research.12268.2
- Gattrell WT, Hopewell S, Young K, Farrow P, White R, Wager E, Winchester CC. Professional medical writing support and the quality of randomised controlled trial reporting: a cross-sectional study. BMJ Open. 2016;6(2):e010329. doi:10.1136/bmjopen-2015-010329 read 9 October 2026. doi.org/10.1136/bmjopen-2015-010329
- Battisti WP, Wager E, Baltzer L, Bridges D, Cairns A, Carswell CI, Citrome L, Gurr JA, Mooney LA, Moore BJ, Pena T, Sanes-Miller CH, Veitch K, Woolley KL, Yarker YE. Good Publication Practice for Communicating Company-Sponsored Medical Research: GPP3. Annals of Internal Medicine. 2015;163(6):461-464. doi:10.7326/M15-0288 read 9 October 2026. doi.org/10.7326/M15-0288
- Wislar JS, Flanagin A, Fontanarosa PB, et al. Honorary and ghost authorship in high impact biomedical journals: a cross sectional survey. BMJ. 2011;343:d6128. doi:10.1136/bmj.d6128 read 9 October 2026. doi.org/10.1136/bmj.d6128
- Das N, Panjabi M. Plagiarism: why is it such a big issue for medical writers? Perspectives in Clinical Research. 2011;2(2):67-71. doi:10.4103/2229-3485.80370 read 9 October 2026. doi.org/10.4103/2229-3485.80370
- Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. Annals of Internal Medicine. 2010;152:726-732. read 9 October 2026. care-statement.org
- Graf C, Battisti WP, Bridges D, Bruce-Winkler V, Conaty JM, Ellison JM, Field EA, Gurr JA, Marx M-E, Patel M, Sanes-Miller C, Yarker YE. Good publication practice for communicating company sponsored medical research: the GPP2 guidelines. BMJ. 2009;339:b4330. doi:10.1136/bmj.b4330 read 9 October 2026. doi.org/10.1136/bmj.b4330
- Woloshin S, Schwartz LM, Casella SL, Kennedy AT, Larson RJ. Press releases by academic medical centers: not so academic? Annals of Internal Medicine. 2009;150:613-618. read 9 October 2026. archive.emwa.org
- Rothman DJ, McDonald WJ, Berkowitz CD, Chimonas SC, DeAngelis CD, Hale RW, et al. Professional medical associations and their relationships with industry: a proposal for controlling conflict of interest. JAMA. 2009;301(13):1367-1372. read 9 October 2026. equator-network.org
- Gotzsche PC, Kassirer JP, Woolley KL, Wager E, Jacobs A, Gertel A, et al. What should be done to tackle ghostwriting in the medical literature? PLoS Medicine. 2009;6(2):e1000023. read 9 October 2026. archive.emwa.org
- Ross JS, Hill KP, Egilman DS, Krumholz HM. Guest authorship and ghostwriting in publications related to rofecoxib: a case study of industry documents from rofecoxib litigation. JAMA. 2008;299:1800-1812. read 9 October 2026. archive.emwa.org
- Angell M. Industry-sponsored clinical research: a broken system. JAMA. 2008;300:1069-1071. read 9 October 2026. archive.emwa.org
- Titus SL, Wells JA, Rhoades LJ. Repairing research integrity. Nature. 2008;453:980-982. read 9 October 2026. archive.emwa.org
- Hill KP, Ross JS, Egilman DS, Krumholz HM. The ADVANTAGE seeding trial: a review of internal documents. Annals of Internal Medicine. 2008;149:251-258. read 9 October 2026. archive.emwa.org
- Norris R, Bowman A, Fagan JM, Gallagher ER, Geraci AB, Gertel A, et al. International Society for Medical Publication Professionals (ISMPP) position statement. Current Medical Research and Opinion. 2007;23:1837-1840. read 9 October 2026. archive.emwa.org
- von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP; STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ. 2007;335:806-808. read 9 October 2026. care-statement.org
- Jacobs A, Wager E. EMWA guidelines on the role of medical writers in developing peer-reviewed publications. Current Medical Research and Opinion. 2005;21:317-321. read 9 October 2026. archive.emwa.org
- von Elm E, Poglia G, Walder B, Tramer MR. Different patterns of duplicate publication: an analysis of articles used in systematic reviews. JAMA. 2004;291(8):974-980. doi:10.1001/jama.291.8.974 read 9 October 2026. doi.org/10.1001/jama.291.8.974
- Steinbrook R. Public registration of clinical trials. New England Journal of Medicine. 2004;351:315-317. doi:10.1056/NEJMp048191 read 9 October 2026. doi.org/10.1056/NEJMp048191
- Hamilton CW, Royer MG; AMWA 2002 Task Force on the Contributions of Medical Writers to Scientific Publications. AMWA position statement on the contributions of medical writers to scientific publications. AMWA Journal. 2003;18:13-16. read 9 October 2026. archive.emwa.org
- Wager E, Field EA, Grossman L. Good publication practice for pharmaceutical companies. Current Medical Research and Opinion. 2003;19(3):149-154. doi:10.1185/030079903125001767 read 9 October 2026. doi.org/10.1185/030079903125001767
- Wager E, Field EA, Grossman L. Good publication practice for pharmaceutical companies: why we need another set of guidelines. Current Medical Research and Opinion. 2003;19(3):147-148. read 9 October 2026. ismpp.org
- Antes G, Chalmers I. Under-reporting of clinical trials is unethical. Lancet. 2003;361:978-979. read 9 October 2026. ismpp.org
- Davidoff F, DeAngelis CD, Drazen JM, Hoey J, Hojgaard L, Horton R, et al. Sponsorship, authorship, and accountability. Annals of Internal Medicine. 2001;135:463-466. read 9 October 2026. ismpp.org
- Rennie D, Flanagin A, Yank V. The contributions of authors. JAMA. 2000;284:89-91. read 9 October 2026. ismpp.org
- Stern JM, Simes RJ. Publication bias: evidence of delayed publication in a cohort study of clinical research papers. BMJ. 1997;315:640-645. read 9 October 2026. ismpp.org
- Easterbrook PJ, Berlin JA, Gopalan R, Matthews DR. Publication bias in clinical research. Lancet. 1991;337:867-872. read 9 October 2026. ismpp.org
Every source above is a peer-reviewed article, a publisher’s record of one, or a standard issued by the body that owns it. Each carries the date it was last read. Where a standard moves, this article is revised rather than left up with a note.
How to cite this article
Pick your referencing style and copy it. Your university or target journal may vary the punctuation — check its guide if it has one.
Pubrica Academy. (2026, October 9). The Evolution of Good Publication Practice: Four Editions and the Events That Prompted Them. Pubrica. https://pubrica.com/academy/concepts-definitions/evolution-of-gpp/
Pubrica Academy. “The Evolution of Good Publication Practice: Four Editions and the Events That Prompted Them.” Pubrica, 9 Oct. 2026, pubrica.com/academy/concepts-definitions/evolution-of-gpp/.
Pubrica Academy (2026) The Evolution of Good Publication Practice: Four Editions and the Events That Prompted Them. Pubrica. Available at: https://pubrica.com/academy/concepts-definitions/evolution-of-gpp/ (Accessed: 15 October 2026).
Pubrica Academy. “The Evolution of Good Publication Practice: Four Editions and the Events That Prompted Them.” Pubrica. October 9, 2026. https://pubrica.com/academy/concepts-definitions/evolution-of-gpp/
Pubrica Academy, ‘The Evolution of Good Publication Practice: Four Editions and the Events That Prompted Them’ (Pubrica, 9 October 2026) <https://pubrica.com/academy/concepts-definitions/evolution-of-gpp/> accessed 15 October 2026.
Pubrica Academy. The Evolution of Good Publication Practice: Four Editions and the Events That Prompted Them. [Internet]. Pubrica; 2026 Oct 9 [cited 2026 Oct 15]. Available from: https://pubrica.com/academy/concepts-definitions/evolution-of-gpp/
Pubrica Academy, “The Evolution of Good Publication Practice: Four Editions and the Events That Prompted Them,” Pubrica, Oct. 9, 2026. [Online]. Available: https://pubrica.com/academy/concepts-definitions/evolution-of-gpp/
@misc{evolution_of_gpp_2026,
author = {{Pubrica Academy}},
title = {The Evolution of Good Publication Practice: Four Editions and the Events That Prompted Them},
howpublished = {Pubrica},
year = {2026},
month = {oct},
url = {https://pubrica.com/academy/concepts-definitions/evolution-of-gpp/},
note = {Accessed: <span data-cite-acc="iso">2026-10-15</span>}
}This article is written to be learned from. Cite it if you are referring to what it says; if you are using the evidence behind it, cite the sources listed above instead.
Edition-gap audit for an existing publication SOP
This audit should be applied once to the organisation’s standing publication procedures. It is not a GPP checklist; it tests whether the procedures were written against the current edition or an earlier one. Any item marked GPP2-era is a clause that has since changed.
GPP EDITION-GAP AUDIT
Document reviewed: ______________________ Version/date: ____________
Edition cited in the document: GPP 2003 / GPP2 / GPP3 / GPP 2022 / none
A. MECHANISM (introduced at GPP2, 2009)
[ ] A written sponsor-author agreement is required BEFORE drafting begins
[ ] Sponsor responsibilities are itemised, not described generally
[ ] Author responsibilities are itemised
[ ] Shared responsibilities are itemised
[ ] The agreement states that the decision to submit rests with the authors
If any box is unchecked, the document predates the GPP2 mechanism in substance,
whatever edition it names.
B. WRITING SUPPORT (position set by AMWA 2003, EMWA 2005, ISMPP 2007)
[ ] Support is disclosed by PERSON, not only by agency
[ ] Employer is named
[ ] Funder is named
[ ] Scope of the support is described
[ ] The writer's consent to be named is recorded
[ ] The document states that writing support is not authorship unless the
ICMJE criteria are met
C. PUBLICATION OF UNFAVOURABLE RESULTS (principle from GPP 2003 onward)
[ ] The procedure commits to publication regardless of direction of result
[ ] There is a named owner for deciding when a study is published
[ ] There is a stated timeframe
D. SCOPE (extended at GPP 2022)
Does the procedure cover, by name:
[ ] Journal articles
[ ] Congress abstracts, posters and presentations
[ ] Plain-language summaries
[ ] Enhanced or digital content (graphical abstracts, video, infographics)
[ ] Registry results postings
[ ] Material intended for patients rather than clinicians
Unchecked items are the GPP 2022 scope gap.
E. EXTERNAL REQUIREMENTS THE EDITIONS FOLLOWED
[ ] Prospective trial registration is required and the number appears in
the methods
[ ] A data sharing statement is required for trial-results manuscripts
[ ] Per-author competing-interest declarations are required
F. ACTIONS
Clauses to update: ______________________________________________
Owner: ______________________ Target date: ____________ Pubrica AcademyWritten and maintained by Pubrica’s subject matter experts. Articles are revised when the underlying standards change, and each article states the date on which it was last reviewed.
How Pubrica can help
Pubrica’s publication-support team reviews an existing sponsor procedure or a manuscript in progress against the current edition, rather than the edition named in the document, and identifies which clauses have changed. In practice, gaps cluster in three areas: a written agreement that postdates the first draft, writing support disclosed by agency rather than by individual, and non-journal outputs that no procedure covers. Pubrica drafts the contributorship, acknowledgement and sponsor-role text and identifies where the guideline is silent and the target journal’s own instructions must govern.